Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 8:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Impaired Glucose Metabolism Clear all
Completed Phase 3 Interventional Results available

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

NCT00614939
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
11
States / cities
Concord, California • Sacramento, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Piedmont Aging, Cognition & Exercise Study-2

NCT02312843
View directory record Official record
Conditions
Mild Cognitive Impairment, Prediabetes
Interventions
Exercise/Aerobic, Exercise/Stretching
Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
50 Years to 89 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Cognitive Effects of Aerobic Exercise for IGT Adults

NCT00220441
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Aerobic exercise
Behavioral
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
55 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
2
States / cities
Seattle, Washington • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.

NCT01098539
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
albiglutide, sitagliptin
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
121
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex

NCT03419195
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Healthy, Overweight, Cardiovascular Risk Factor
Interventions
Cardiovascular exercise training
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

NCT02836873
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 9, 2026, 8:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Impaired Adipogenesis in Insulin Resistance: Pilot Clinical and In Vitro Studies

NCT00560469
View directory record Official record
Conditions
Adipocyte Differentiation, Insulin Resistance
Interventions
Administration of 70% deuterated water
Other
Lead sponsor
University of Vermont
Other
Eligibility
40 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
South Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

NCT03819153
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
3,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
117
States / cities
Tuscumbia, Alabama • Chula Vista, California • Concord, California + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 9, 2026, 8:37 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Study of Post-meal Blood Sugar Peaks in Association With Vascular Disease in Childhood Obesity

NCT00846521
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance, Impaired Glucose Tolerance, Cardiovascular Disease
Interventions
Acarbose
Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 25 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 1 Interventional

Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment

NCT05601583
View directory record Official record
Conditions
Type 2 Diabetes, Mild Cognitive Impairment
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years to 100 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 4 Interventional

Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

NCT01239004
View directory record Official record
Conditions
Dyslipidemia, Hyperlipidemia, Hyperglycemia
Interventions
Placebo, Colesevelam
Drug
Lead sponsor
Radiant Research
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Not applicable Interventional

Improving Autonomic Function and Balance in Diabetic Neuropathy

NCT01864460
View directory record Official record
Conditions
Diabetes, Neuropathy, Impaired Glucose Tolerance
Interventions
lifestyle modification
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

NCT00438568
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mitochondrial Impairment in Muscle Insulin Resistance

NCT00222924
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
weight loss/ exercise
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
30 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2007 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

NCT03319173
View directory record Official record
Conditions
Mild Cognitive Impairment, Metabolic Syndrome
Interventions
Dietary intervention
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Maple Grove, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 9, 2026, 8:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Pulsatile Insulin Secretion (A Study Investigating the Effects of Partial Pacreatectomy on Glucose Metabolism)

NCT00841867
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 9, 2026, 8:37 PM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

NCT01548651
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 4 Interventional Results available

Linagliptin's Effect on CD34+ Stem Cells

NCT02467478
View directory record Official record
Conditions
Type 2 Diabetes, Impaired Renal Function
Interventions
Linagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
30 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

NCT03697109
View directory record Official record
Conditions
Cushing Syndrome
Interventions
Relacorilant, Placebo
Drug · Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
32
States / cities
Phoenix, Arizona • Los Angeles, California • Torrance, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 9, 2026, 8:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Night Owl Metabolism

NCT06507722
View directory record Official record
Conditions
PreDiabetes, Overweight, Impaired Glucose Tolerance
Interventions
Timing of OGTT, Timing of Standardized Meal
Diagnostic Test · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 23 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Enhancing Fitness in Older Pre-diabetic Veterans

NCT00594399
View directory record Official record
Conditions
Impaired Glucose Tolerance, Obesity, Diabetes
Interventions
Physical Activity Counseling
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
60 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 9, 2026, 8:37 PM EDT
Completed No phase listed Observational

Evaluation of Low Source of Signal in SCOUT DS

NCT01339637
View directory record Official record
Conditions
Metabolic Syndrome, Impaired Glucose Tolerance, Gestational Diabetes
Interventions
Not listed
Lead sponsor
VeraLight, Inc.
Industry
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 9, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessing the Impact of a Plant-Based Diet for Diabetes Prevention

NCT06571279
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Interventions
Plant-based diet
Other
Lead sponsor
Jean L. Fry
Other
Eligibility
30 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 9, 2026, 8:37 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency

NCT07385547
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 9, 2026, 8:37 PM EDT